Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Bio Products Laboratory Ltd., Elstree, WD6 3BX, United Kingdom
Pharmacotherapeutic group: immune sera and immunoglobulins: Human varicella immunoglobulin
ATC code: J06BB03
Human Varicella-Zoster Immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against varicella-zoster virus.
Human Varicella-Zoster Immunoglobulin for intramuscular administration is bioavailable in the recipient’s circulation after a delay of 2-3 days.
Human Varicella-Zoster Immunoglobulin has a half-life of about 3-4 weeks. This half-life may vary from patient to patient.
IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.
Human Varicella-Zoster Immunoglobulin is a preparation of human plasma proteins, so safety testing in animals is not particularly relevant to the safety of use in man.
Acute toxicity studies in rats and mice with immunoglobulins showed species specific reactions which bear no relevance to administration in humans.
Repeated dose toxicity testing and embryo-foetal toxicity studies are impracticable due to an induction of, and interference with antibodies to human protein.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
